Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate "DYAI-100" and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic Announces Change in Board and Management Leadership Roles
Dyadic to Attend Industry Events in April
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic to Attend Future Food Tech Event March 21 - 22, 2024 in San Francisco, California
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
CORRECTION - Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.